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The vasohibin (VASH) family consists of two genes, VASH1 and VASH2. VASH1 is
mainly expressed in vascular endothelial cells and suppresses angiogenesis in an
autocrine manner, whereas VASH2 is mainly expressed in cancer cells and exhi-
bits pro-angiogenic activity. Employing adenomatous polyposis coli gene mutant
mice, we recently reported on the role of Vash2 in the spontaneous formation of
intestinal tumors. In this study, we used K19-Wnt1/C2mE (Gan) mice and exam-
ined the role of Vash2 in spontaneous gastric cancer formation. Gan mice sponta-
neously develop gastric tumors by activation of Wnt and prostaglandin E2
signaling pathways in gastric mucosa after 30 weeks of age. Expression of Vash2
mRNA was significantly increased in gastric tumor tissues compared with normal
stomach tissues. When Gan mice were crossed with the Vash2-deficient
(Vash2LacZ/LacZ) strain, gastric cancer formation was significantly suppressed in
Vash2LacZ/LacZ Gan mice. Normal composition of gastric mucosa was partially main-
tained in Vash2LacZ/LacZ Gan mice. Knockout of Vash2 caused minimal reduction of
tumor angiogenesis but a significant decrease in cancer-associated fibroblasts
(CAF) in tumor stroma. DNA microarray analysis and real-time RT-PCR showed
that mRNA levels of epiregulin (Ereg) and interleukin-11 (Il11) were significantly
downregulated in gastric tumors of Vash2LacZ/LacZ Gan mice. Furthermore, condi-
tioned medium of gastric cancer cells stimulated migration of and a-smooth mus-
cle actin expression in fibroblasts, whereas conditioned medium of VASH2
knockdown cells attenuated these effects in vitro. These results suggest that
VASH2 plays an important role in gastric tumor progression via the accumulation
of CAF accompanying upregulation of EREG and IL-11 expression.
G astric cancer is the third leading cause of cancer-relateddeath in Japan. Risk factors for gastric cancer include
Helicobacter pylori infection, host genetic susceptibility and
other environmental factors, and multiple genetic mutations,
epigenetic alterations and aberrant molecular signaling path-
ways are involved in its development.(1)
The treatment of gastric cancer has evolved in the past three
years. Molecular characterization of gastric cancer has pro-
vided clues for treatment development, and the introduction of
agents targeting human epidermal growth factor (EGF) recep-
tor 2 and vascular endothelial growth factor (VEGF) family/
VEGF receptor has brought this disease into the era of molecu-
lar and personalized medicine.(2)
We searched for and isolated novel angiogenesis regulators
that we have designated as vasohibin-1 (VASH1) and vaso-
hibin-2 (VASH2). VASH1 is an endothelium-derived angiogen-
esis inhibitor,(3) whereas VASH2 is a homologue of VASH1
that acts as an angiogenesis stimulator.(4,5) These two regulators
are devoid of the classical secretory signal sequence but are
efficiently secreted when they form a complex with small
vasohibin-binding protein.(6,7) Of note, VASH2 is produced by
cancer cells such as ovarian carcinoma, hepatocellular carci-
noma and intestinal adenocarcinoma, and promotes tumor
growth by stimulating tumor angiogenesis.(8–10) Using xeno-
graft models of human ovarian cancer, we recently reported that
targeting of VASH2 by exogenous administration of siRNA or
a neutralizing antibody specific for VASH2 inhibits tumor
growth by attenuating tumor angiogenesis.(11,12) Furthermore,
when an experimental model for spontaneous adenomatous
polyposis, the adenomatous polyposis coli multiple intestinal
neoplasia (ApcMin/+) mouse, is crossed with the Vash2lacZ/lacZ
mouse, the number of intestinal tumors significantly decreases
in association with normalization of tumor vessels.(10) The
expression of VASH2 has also been documented in human gas-
tric cancer cell lines,(13) but the significance of VASH2 in gas-
tric cancer development is not well defined.
Spontaneous carcinogenic mouse models are useful for gain-
ing insight into the pathogenesis and molecular mechanisms of
cancers. The K19-Wnt1/C2mE (Gan for Gastric neoplasia)
mouse was recently established by the transgenic expression of
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Wnt1, cyclooxygenase-2 and microsomal prostaglandin E syn-
thase-1 under a Keratin 19 promoter in gastric epithelial cells,
recapitulating human gastric tumors not only in terms of
molecular mechanism but also tumor pathology.(14) Here we
used Gan mice, crossed with Vash2lacZ/lacZ mice, and exam-
ined the significance of VASH2 in gastric tumor growth and
the tumor stromal microenvironment.
Materials and Methods
Mouse models. As noted, Gan mice highly express Wnt1,
cyclooxygenase-2 and microsomal prostaglandin E synthase-1
under Keratin 19 promoter activity in gastric epithelial cells
and generate gastric tumors after 30 weeks of birth, as previ-
ously reported.(14) Vash2LacZ/LacZ mice were maintained as
described earlier,(4) and Gan mice were mated with Vash2LacZ/
LacZ mice to generate Vash2LacZ/LacZ Gan mice. For the tumor
development analyses, mice were euthanized and examined at
30 weeks of age. All animal experiments were carried out
according to the protocol approved by the Committee on Ani-
mal Experimentation of Tohoku University, Japan.
Histological and immunohistochemical analyses. Gan mice at
age 30 weeks were anesthetized and transcardially perfused
with PBS followed by 4% paraformaldehyde. Stomachs were
extracted and incubated overnight with 4% paraformaldehyde,
dehydrated in graded ethanol and xylene, and embedded in
paraffin wax. Vertical sections (5 lm) of the entire gastric
mucosa were prepared for conventional H&E staining or
immunohistochemical staining. For immunohistochemical
staining, tissue sections were autoclaved in citrate buffer
(pH 6.0) for 5 min for antigen retrieval prior to incubation
with primary antibodies. Antibodies against the H+, K+-
ATPase (MBL, Nagoya, Japan), F4/80 (Serotec, Oxford, UK),
alpha smooth muscle actin (aSMA; Sigma, St. Louis, MO,
USA), Tenascin-C (TNC; Abcam, Cambridge, MA, USA), Ki-
67, CD31 and Vimentin (VIM; Cell Signaling, Beverly, MA,
USA) were used as the primary antibodies. Staining signals
were visualized using Histofine Simple Stain MAX PO
(Nichirei, Tokyo, Japan) followed by counterstaining with
hematoxylin. Microphotographs were obtained using an
MC120 HD camera attached to a Leica DM 2000 LED micro-
scope (Leica Microsystems K.K., Tokyo, Japan). For fluores-
cence immunostaining, antibodies conjugated with Alexa Fluor
488 or Alexa Fluor 555 (Thermo Fisher Scientific, Waltham,
MA, USA) were used as the secondary antibodies. Nuclei were
then counterstained using ToPro-3 (Thermo Fisher Scientific).
Fluorescence images were captured using a Fluoview FV1000
confocal microscope system (Olympus, Tokyo, Japan).
Measurement of mucosal thickness. The mucosal thickness of
gastric tumors was measured from micrographs of H&E-
stained vertical sections of entire gastric tumors using LAS
Software (Leica Microsystems K.K.). Relative mucosal thick-
ness of samples from Vash2LacZ/LacZ Gan mice was calculated
in comparison with the mean of the control Gan mice.
In situ hybridization. In situ hybridization was performed
with the ISH Reagent Kit (Genostaff, Tokyo, Japan) according
to the manufacturer’s instructions. Tissue sections were de-par-
affinized with G-Nox and rehydrated through an ethanol series
and PBS. The sections were: fixed with 10% NBF (10% for-
malin in PBS) for 15 min at room temperature (RT) and
washed in PBS; treated with 4 lg/mL Proteinase K (Wako
Pure Chemical, Osaka, Japan) in PBS for 10 min at 37°C and
washed in PBS; re-fixed with 10% NBF for 15 min at RT
and washed in PBS; placed in 0.2 N HCl for 10 min at RT
and washed in PBS; and placed within a Coplin jar containing
19 G-Wash (Genostaff), equal to 19 SSC. Hybridization was
performed with probes corresponding to the nucleotide posi-
tions 1321–2001 of mouse Vash2 mRNA (GenBank accession
number NM_144879.2) at concentrations of 300 ng/mL in G-
Hybo-L (Genostaff) for 16 h at 60°C. After hybridization, the
sections were washed in 19 G-Wash for 10 min at 60°C and
50% formamide in 19 G-Wash for 10 min at 60°C.
Sections then were washed twice in 19 G-Wash for 10 min
at 60°C, twice in 0.19 G-Wash for 10 min at 60°C, and twice
in TBST (0.1% Tween20 in TBS) at RT. After treatment with
19 G-Block (Genostaff) for 15 min at RT, the sections were
incubated with anti-digoxigenin AP conjugate (Roche Diagnos-
tics, Mannheim, Germany) diluted 1:2000 with 950G-Block
(Genostaff) in TBST for 1 h at RT. The sections were washed
twice in TBST and then incubated in 100 mM NaCl, 50 mM
MgCl2, 0.1% Tween20, 100 mM Tris-HCl, pH 9.5. Coloring
reactions were performed with NBT/BCIP solution (Sigma-
Aldrich, St. Louis, MO, USA) overnight and then washed in
PBS. The sections were counterstained with Kernechtrot stain
solution (Muto Pure Chemicals, Tokyo, Japan) and mounted
with G-Mount.
RT-PCR and quantitative real-time RT-PCR. Total RNA was
extracted from mouse tissues and cultured cells using QIAzol
Lysis Reagent (QIAGEN, Hilden, Germany) and purified using
the RNeasy Mini Kit (QIAGEN). First-strand cDNA was synthe-
sized by reverse transcriptase using ReverTra Ace (TOYOBO,
Osaka, Japan). PCR was performed using sets of primers specific
for the target genes described below. Thermal cycler conditions
were 20–30 cycles at 94°C for 15 s for denaturing, at 56°C for
30 s for annealing, and at 72°C for 45 s for extension. PCR
products were separated on a 1% agarose gel and visualized
under ultraviolet by ethidium bromide staining. Quantitative
real-time RT-PCR was performed using the CFX96 real-time
RT-PCR detection system (Bio-Rad Laboratories, Hercules, CA,
USA) according to the manufacturer’s instructions. PCR condi-
tions consisted of an initial denaturation step at 95°C for 3 min,
followed by 40 cycles of 10 s at 95°C, 10 s at 56°C and 30 s at
72°C. Relative mRNA levels of target genes were normalized to
beta-2-microglobulin (B2m) mRNA level. The specific primer
pairs for target genes are summarized in Table S1. Specific pri-
mer pairs for detection of CD44 splicing variant (CD44v) tar-
geted exons 5 and 16 of CD44 mRNA.(15)
Microarray analysis. Total RNA was extracted from gastric
tumor tissues as described above. The quality of total RNA was
confirmed by an Agilent 2100 Bioanalyzer (Agilent Technolo-
gies, Santa Clara, CA, USA). The cRNA was synthesized and
labeled with Cy3 using the Low Input Quick-Amp Labeling Kit
(Agilent Technologies). The Cy3-labeled cRNA samples were
subjected to hybridization to SurePrint G3 Mouse GE Microar-
ray chips (Agilent Technologies) using a Gene Expression
Hybridization Kit. Fluorescence signals in the chips were
detected by an Agilent microarray scanner (Agilent Technolo-
gies) and quantified using Feature Extraction software (Agilent
Technologies).
Cell cultures. FU97 cells (a human stomach cancer cell line)
and SF-TY cells (a human skin fibroblast cell) were obtained
from the Japanese Collection of Research Bioresources Cell
Bank (Osaka, Japan). FU97 cells were cultured in DMEM
(Wako Pure Chemical) supplemented with 10% heat-inacti-
vated FBS (SAFC Biosciences, Lenexa, KS, USA) and 10 lg/
mL of recombinant human insulin (Wako Pure Chemical). SF-
TY cells were maintained in DMEM supplemented with 10%
FBS and non-essential amino acids.
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Knockdown of VASH2 by shRNA. FU97 cells were transfected
with the VASH2 shRNA expression vector or its control mock
vector using FuGENE HD Transfection Reagent (Promega,
Madison, WI, USA) and were selected in culture medium con-
taining 10 lg/mL puromycin (Wako Pure Chemical), as
reported previously.(8)
Fibroblast proliferation and migration. FU97 cells and
VASH2 knockdown (shVASH2) clones were plated in 60-mm
dishes at 5 9 105 cells and cultured overnight in the culture
medium. The following day, the medium was replaced by
DMEM containing 0.5% FBS. The conditioned medium was
collected 48 h later and filtered through a MILLEX-GP PES
0.22-lm filter (Millipore, Bedford, MA, USA). Cell prolifera-
tion was measured using a BrdU Cell Proliferation ELISA Kit
(Abcam). Cells were plated in a 96-well plate at 5 9 103 cells
per well and starved in DMEM containing 0.5% FBS for 16 h.
Cells were then treated with conditioned media (CM) from
FU97 cells or shVASH2 clones and labeled with BrdU for
24 h. Incorporated BrdU was detected according to the manu-
facturer’s instructions. Migratory activity of fibroblasts was
measured by modified Boyden chamber assay.(6) SF-TY cells
were seeded on the upper chambers (inserts) of the Boyden
chamber (8.0 lm pore size, Corning) at 2 9 105 cells. The
lower chamber was filled with 600 lL of CM from FU97 cells
or shVASH2 clones. After incubation for 4 h, SF-TY cells that
migrated across the membrane were fixed with methanol,
stained with DAPI (Sigma-Aldrich), and counted in nine fields
per insert in a blinded manner.
Statistical analysis. Data are expressed as mean  SD and
were analyzed using unpaired Student’s t-tests. A value of
P < 0.05 was considered to denote statistical significance.
Results
Increased expression of VASH2 in gastric tumor cells in Gan
mice. Previous reports demonstrated that VASH2 is highly
expressed in various types of human tumor tissues as well as
in established cancer cell lines.(8,9,13,16–20) Shen et al.(13)
reported that both human gastric cancer cell lines and experi-
mentally prepared tumor-associated macrophages express
VASH2 mRNA in an in vitro culture system. However, the
roles of VASH2 in spontaneous gastric tumor growth are not
fully understood. Gan mice spontaneously generate gastric
tumors by simultaneous signal activation of both Wnt and
prostaglandin E2 (PGE2) in gastric epithelia under keratin-14
promoter activity.(21–27) We first examined the expression level
of Vash2 mRNA in gastric tumors spontaneously developed in
Gan mice at 30 weeks of age. As shown in Figure 1(a), RT-
PCR analysis showed enhanced expression of CD44 splicing
variants (CD44v) and Vash2 in gastric tumors of Gan mice,
whereas normal stomach tissues expressed low levels of Vash2
and no CD44v, as previously reported.(15,28) According to
CD44v mRNA expression, increased expression of Vash2
mRNA was detected in Gan mice gastric tumors (Fig. 1a).
Real-time RT-PCR analysis showed that the expression level
of Vash2 mRNA in Gan mouse gastric tumors was approxi-
mately three times higher than in normal stomachs of wild-
type mice (Fig. 1b).
We then performed in situ hybridization for mouse Vash2
transcript in tissue sections of Gan mouse gastric tumors at
30 weeks of age. Signals for Vash2 mRNA transcripts visual-
ized by antisense probes were detected in gastric tumors of
Gan mice but not in normal stomach (Fig. 1c). As shown in
Figure 1(d), the signals were mainly localized in dysplastic
epithelial cells (black arrowheads), whereas they were hardly
observed in other stromal cells (white arrowheads). These
results indicate that dysplastic epithelial cells express Vash2
mRNA in Gan mice.
Suppression of gastric tumor growth in Vash2-deficient Gan
mice. To investigate the role of VASH2 in spontaneous gastric
tumor development, we bred Gan mice with Vash2-deficient
mice (Vash2LacZ/LacZ) to obtain Vash2-deficient Gan mice
(Vash2LacZ/LacZ Gan) and examined the phenotypic differences
Fig. 1. Expression of Vash2 mRNA in gastric tumors. (a) RT-PCR for
CD44 and Vash2 mRNA in the normal stomachs of wild-type mice
(n = 4) and gastric tumors of Gan mice (n = 4) at 30 weeks of age.
The expression level of B2m mRNA was used as an internal control.
PCR products of CD44 show three types of splicing variant isoforms
(CD44v) and standard form (CD44s).(15,28) (b) The relative expression
level of Vash2 mRNA in Gan mouse gastric tumors (n = 4) at 30 weeks
of age compared to wild-type normal stomachs (n = 4). The expression
level of Vash2 mRNA was normalized to the B2m mRNA level.
Mean  SD shown. *P < 0.05 versus wild-type. (c) In situ hybridization
of Vash2 mRNA in Gan mouse gastric tumor tissue. Mouse Vash2-spe-
cific antisense and sense probes were hybridized with cross-sections of
Gan mouse gastric tumors and normal stomach at 30 weeks of age.
Representative images with antisense (right) and sense (center) are
shown. The left panel shows representative images of H&E staining.
Scale bar: 100 lm. (d) A high magnification micrograph showing
Vash2-expressing dysplastic epithelial cells (black arrowheads) in Gan
mouse gastric tumors. White arrowheads indicate stromal cells. Scale
bar: 100 lm.
© 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
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in gastric tumors developed in those mice. As shown in Fig-
ure 2(a), development of gastric tumors was observed in Gan
mice at 30 weeks of age, as reported previously.(14) Of
note, gastric tumor growth was obviously suppressed in
Vash2LacZ/LacZ Gan mice compared with that in Gan mice
(Fig. 2a,b). The mean of histologic tumor thickness was signif-
icantly reduced by knockout of Vash2 (Fig. 2b,c).
Immunohistochemical staining for Ki-67 antigen in paraffin
sections of those gastric tumor tissues showed that Ki-67-posi-
tive proliferating cells were frequently observed in the entire
gastric dysplastic epithelia of Gan mice tumors, whereas most
proliferating cells were limited to the proliferating zone at the
gland neck area in gastric tumors of Vash2LacZ/LacZ Gan mice
(Fig. 3a,c). To confirm the distribution of gastric parietal cells
in gastric tumors, we performed immunostaining with antibody
for the proton pump (H+, K+-ATPase), used as a marker of
parietal cells. As shown in the center panel of Figure 3(b), a
small number of gastric parietal cells was observed in Gan
mice gastric tumors (Fig. 3d), indicating an architectural disor-
der of gastric tumor tissues, as reported previously.(25) How-
ever, a numerous parietal cell population was still maintained
in gastric tumors of Vash2LacZ/LacZ Gan mice (Fig. 3b,d).
These results indicate that the lack of the Vash2 gene sup-
pressed spontaneous gastric cancer development.
Effect of Vash2 on stromal activation in gastric cancer. The
tumor stromal microenvironment (e.g. tumor angiogenesis,
expansion of cancer associated fibroblasts (CAF) and infiltra-
tion of immune cells) plays crucial roles in tumor development
and progression. Therefore, we examined whether Vash2 defi-
ciency might affect the stromal microenvironment in gastric
tumors. Immunofluorescence staining of tissue sections of Gan
mouse gastric tumors with anti-CD31 antibody showed that a
large number of capillary blood vessels are generated in these
tumors (Fig. 4a, left panel). In comparison with Gan mice,
slightly fewer capillaries were observed in gastric tumors of
Vash2LacZ/LacZ Gan mice (Fig. 4a, right panel), but overall this
difference was not statistically significant (Fig. 4b). Tumor
blood vessels are typically fragile and leaky because of their
immature structure accompanied by poor pericyte coverage.
We previously reported that Vash2 depletion causes vascular
normalization with restoration of pericyte coverage.(10,17) How-
ever, Vash2 deficiency did not affect pericyte coverage in the
Gan mouse model (data not shown). Inflammatory responses
via infiltrated monocytes/macrophages also have a critical
effect on spontaneous gastric tumor growth. Immunohisto-
chemical staining for the F4/80 antigen, a marker specific for
mouse macrophages, revealed numerous macrophages infiltrat-
ing into gastric tumor stroma in Vash2LacZ/LacZ Gan and Gan
mouse tumors (Fig. 4c,d), suggesting that Vash2 disruption
might not affect macrophage infiltration in this mouse model.
Next, we evaluated the expansion of CAF in gastric tumor
stroma by immunostaining for aSMA and VIM. Numerous
VIM-positive and/or aSMA-positive CAF were detected in
entire Gan mouse tumor tissues, whereas CAF were sparsely
observed in Vash2LacZ/LacZ Gan tumors (Fig. 5a,b). Immunoflu-
orescence staining for another CAF marker, Tenascin C
(TNC), also showed that Vash2 deficiency significantly
reduced the stromal expansion of TNC-positive CAF (Fig. 5c,
d) compared with Gan mice. These results suggested that
VASH2 produced by tumor cells might accelerate the expan-
sion of CAF into tumor stroma in addition to its pro-angio-
genic activity.
Downregulation of expression of Epiregulin and interleukin-11
by Vash2 depletion in gastrointestinal tumors. To identify genes
with expression changes in gastric tumor tissues by knockout
of the Vash2 gene, we comprehensively compared mRNA
expression profiles between Gan mouse gastric tumors and
Vash2LacZ/LacZ Gan mouse gastric tumors by a DNA
Fig. 2. Suppression of gastric tumor growth by
knockout of the Vash2 gene. (a) Representative
macroscopic images of wild-type normal stomach
and Gan and Vash2LacZ/LacZ Gan mouse gastric
tumors at 30 weeks of age. (b) Representative
images of H&E staining of Gan mouse (top) and
Vash2LacZ/LacZ Gan mouse (bottom) gastric tumors at
30 weeks of age. Scale bar: 2 mm. (c) Relative
gastric mucosal thickness of Vash2LacZ/LacZ Gan
mouse gastric tumors (n = 11) to the mean level of
Gan mouse tumors (n = 12) at 30 weeks of age.
Each circle indicates the relative tumor thickness of
individual mice. **P < 0.01 versus Gan mouse
tumors.
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microarray analysis. In Vash2LacZ/LacZ Gan mouse gastric
tumors, 11 genes were upregulated (>2.0 fold) and 164 genes
downregulated (<0.5 fold) compared with Gan mouse gastric
tumors (Tables S2 and S3). Functional classification by Gene
Ontology terms showed that upregulated genes were enriched
for circadian rhythmic processes corresponding to Dbp, Hlf,
Per3 and Tef. Indeed, real-time RT-PCR analysis showed that
mRNA expression levels of Hlf and Dbp were significantly
upregulated in Vash2LacZ/LacZ Gan mouse tumors compared to
Gan mouse tumors (Fig. 6a). In contrast hand, Gene Ontology
terms for downregulated genes were classified to many func-
tions, including regulation of gene expression, biosynthesis,
cell proliferation and defense response. Downregulation of
stem cell/cancer stem cell markers (CD44 and CD133) and
vascular endothelial cell markers (Edn1 and Tie2) correlated
with the suppression of cancer cell proliferation and tumor
angiogenesis caused by Vash2 disruption, as shown in Fig-
ures 3(a) and 4(a), respectively. A significant reduction in
mRNA levels of CD44 and CD133 was confirmed by real-time
RT-PCR analysis (Fig. 6b), whereas Vash2 deficiency did not
significantly change mRNA levels of vascular endothelial cell
markers and typical angiogenic factors, such as Vegfa and
fibroblast growth factor 2 (Fgf2) (Fig. 6c,d). Here, we focused
on interleukin-11 (IL-11, a member of the IL-6 family) and
Epiregulin (Ereg, a member of the EGF family), listed in
Table S3 as downregulated genes, because previous reports
suggested that CAF might promote gastrointestinal tumor
growth through production of IL-6 family and EGF
family.(21,22,29–32) By real-time RT-PCR analysis we confirmed
that the mRNA expression levels of Ereg, Il11 and Il6 were
significantly reduced in Vash2LacZ/LacZ Gan mouse tumors
compared to Gan mouse tumors (Fig. 6e).
Using ApcMin/+ mice, we recently reported the role of
VASH2 in the spontaneous formation of intestinal tumors. The
Vash2-deficient ApcMin/+ mice (Vash2LacZ/LacZ ApcMin/+)
showed a reduced number of polyps alongside the attenuation
of tumor angiogenesis as compared to ApcMin/+ mice.(10) We
next carried out a DNA microarray analysis and identified 17
upregulated genes and 19 downregulated genes in intestinal
polyps of Vash2LacZ/LacZ ApcMin/+ mice compared with ApcMin/+
mice (Tables S4 and S5). Comparative analysis of mRNA
expression profiles obtained from Gan mouse gastric tumors
and ApcMin/+ intestinal polyps revealed that three genes (Ereg,
Il11 and Tmem190) were commonly downregulated in gastric
tumors and intestinal polyps of Vash2-deficient mice
(Fig. S1a). There was no overlap of upregulated genes (data
not shown). Indeed, Ereg and Il11 mRNA was significantly
downregulated in polyps of Vash2LacZ/LacZ ApcMin/+ mice com-
pared to ApcMin/+ mice (Fig. S1b), suggesting that VASH2
promotes expression of EREG and IL-11 in gastrointestinal
tumorigenesis.
Suppression of fibroblast activation by knockdown of VASH2
in gastric cancer cells in vitro. We finally examined whether
VASH2 expressed in human gastric cancer cells affects fibrob-
last expansion in vitro. The expression of VASH2 mRNA in
human gastric cancer cell line FU97 was significantly higher
Fig. 3. Effect of Vash2 depletion on proliferation
of gastric tumor cells and population of gastric
parietal cells. (a, b) Representative images of
immunohistochemical staining for Ki-67 antigen (a)
and H+, K+-ATPase (b) of normal stomach (left),
Gan mouse (center) and Vash2LacZ/LacZ Gan mouse
(right) gastric tumors. Asterisk in (a) shows the
proliferating zone in the gland neck area.
Arrowheads in (b) indicate H+, K+-ATPase
expressing gastric parietal cells. Scale bars: 200 lm.
(c) Relative Ki-67 positive dysplastic epithelial cell
index in Vash2LacZ/LacZ Gan mice to that in Gan
mouse (n = 6 fields analyzed from three
independent animals). (d) Relative parietal cell
index in Gan mouse and Vash2LacZ/LacZ Gan mouse
gastric tumors to that in normal stomachs (n = 6
fields analyzed from three independent animals).
All quantitative data show mean  SD. *P < 0.05
versus Gan mouse tumors.
© 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
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Fig. 4. Effect of Vash2 depletion on tumor
angiogenesis and macrophage infiltration. (a)
Representative images of immunohistochemical
staining for CD31 (green) of Gan mouse (left) and
Vash2LacZ/LacZ Gan mouse (right) gastric tumors at
30 weeks of age. Nuclei were stained with TOPRO-3
(blue). Scale bars: 200 lm. (b) Quantification of the
percentage of CD31-positive vascular vessel area to
total tumor area (n = 8 fields analyzed from three
independent animals). (c) Representative images of
immunohistochemical staining for F4/80 of Gan
mouse (left) and Vash2LacZ/LacZ Gan mouse (right)
gastric tumors at 30 weeks of age. Counterstaining
of nuclei was performed with hematoxylin. Scale
bars: 200 lm. (d) Quantification of the percentage
of F4/80 positive area to total tumor area (n = 12
fields analyzed from three independent animals).
All quantitative data show mean  SD. *P < 0.05
versus Gan mouse tumors. N.S., not significant.
Fig. 5. Suppression of cancer-associated fibroblast
expansion in gastric tumor stroma by Vash2
knockout. (a) Representative images of a double-
fluorescent immunostaining for aSMA and VIM of
Gan and Vash2LacZ/LacZ Gan mouse gastric tumors at
30 weeks of age. Nuclei were stained with TOPRO-3
(blue). Scale bars: 200 lm. Inset, high
magnification. (b) Quantification of the
percentages of aSMA-positive and VIM-positive
areas to total gastric tumor area (n = 6 fields
analyzed from three independent animals). (c)
Representative images of a fluorescent
immunostaining for TNC of Gan and Vash2LacZ/LacZ
Gan mouse gastric tumors at 30 weeks of age.
Nuclei were stained with TOPRO-3 (blue). Scale
bars: 200 lm. (d) Quantification of the percentage
of TNC-positive area to total gastric tumor area
(n = 6 fields analyzed from three independent
animals). All quantitative data show mean  SD.
*P < 0.05 versus Gan mouse tumors. N.S., not
significant.
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than that in human fibroblast SF-TY cells (Fig. 7a). We iso-
lated VASH2 knockdown cell lines (shVASH2-1 and -2) using
shRNA (Fig. 7b) and performed a loss-of-function experiment
in vitro. CM of parent FU97 cells and mock control cells stim-
ulated migration of and ACTA2 (aSMA) expression in SF-TY
cells (Fig. 7c,d). Importantly, CM of shVASH2 cells signifi-
cantly attenuated the stimulatory effects. There was no signifi-
cant effect on proliferation of SF-TY cells (Fig. 7c).
These results suggested that VASH2 produced by cancer
cells influences CAF expansion and gastrointestinal tumor
growth through upregulation of EREG and IL-11gene expres-
sion, in addition to its proangiogenic activity (Fig. 8).
Discussion
Previous studies have reported that VASH2 produced from
cancer cells promotes tumor growth by stimulating tumor
angiogenesis.(8,9) VASH2 is secreted from cancer cells and acts
on neighboring vascular endothelial cells as a paracrine angio-
genesis stimulator. Most studies on the role of VASH2 in
tumor growth have used allograft and xenograft models of
established cancer cell lines. In this work, we employed Gan
mice as a spontaneous gastric tumor developmental model and
confirmed that knockout of Vash2 in Gan mice attenuates
gastric tumor growth with a slight reduction in tumor angio-
genesis. In addition to this proangiogenic activity, we found a
novel role for VASH2 in the tumor stromal microenvironment,
namely CAF. The increase in CAF is one of the characteristic
features of gastric cancer in Gan mice.(19) Vash2 depletion dra-
matically reduced the expansion of CAF in gastric tumor
stroma along with downregulation of Ereg, Il6 and Il11
expression. We also confirmed that the expression of circadian
genes (Dbp, Hlf, Per3 and Tef) and of cancer stem cell mark-
ers (CD44 and CD133) is upregulated and downregulated,
respectively, in Vash2LacZ/LacZ Gan mouse tumors. These
changes might reflect suppression of tumor progression by
knockout of Vash2 because previous reports have shown
downregulation of circadian genes in various tumors.(33–35)
Using the ApcMin/+ mouse model, we recently demonstrated
that Vash2 depletion causes a reduced number of polyps along-
side attenuation of tumor angiogenesis. Here, we also con-
firmed the reduced expression of Ereg and Il11 in intestinal
polyps of Vash2-deficient ApcMin/+ mice as well as gastric
tumors of Vash2-deficient Gan mice. EREG and IL-11 play a
crucial role in gastrointestinal tumor growth, progression and
chemoprevention through crosstalk between EGFR and gp130
signaling.(24,32,36–39) Enhanced expression of the Ereg gene has
also been found in gastric cancer cells.(40) Oshima et al. report
Fig. 6. Vash2 depletion downregulates mRNA
levels of Ereg and Il11 in Gan mouse gastric tumors.
The mRNA levels of indicated genes in gastric
tumors of Vash2LacZ/LacZ Gan mouse at 30 weeks of
age (n = 4) relative to those in gastric tumors of
Gan mouse were determined by real-time RT-PCR
analysis. The mRNA expression levels were
normalized to B2m mRNA level. All quantitative
data show mean  SD. *P < 0.05 versus Gan mouse
gastric tumors. N.S., not significant.
© 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
on behalf of Japanese Cancer Association.
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PGE2 pathway-dependent Ereg expression by gastric epithelial
cells and macrophages in Gan mouse gastric tumors.(24) Of
importance, other recent reports have suggested that CAF as
well as cancer cells are a major supplier of Ereg and IL-11 in
tumor stroma.(37–39,41,42) In this study, we showed that Vash2
disruption influences CAF expansion but not a population of
macrophages infiltrating into the gastric tumor stroma. There-
fore, it is possible that VASH2 stimulates the expression of
EREG and IL-11 in CAF and cancer cells.
Cancer associated fibroblasts in Gan mice produce VEGFA
and promote tumor angiogenesis;(21) however, our data showed
that Vash2 depletion did not affect Vegfa mRNA level despite
reduced CAF expansion. We performed double immunostain-
ing for aSMA and VIM and observed three types of CAF sub-
populations (aSMA-positive, VIM-positive and double-positive
cells), suggesting that CAF are a heterogeneous population in
the tumor microenvironment.(43,44) €Ohlund et al. recently iden-
tified distinct populations of inflammatory and myofibroblastic
CAF in pancreatic cancer. The inflammatory CAF had low
aSMA expression and concomitantly produced inflammatory
factors, such as IL-6, IL-11 and leukemia inhibitory factor.(42)
Therefore, it is possible that VASH2 may specifically affect
certain subtypes of CAF that express higher levels of IL-
11and/or EREG than other subtypes.
Transforming growth factor-b (TGF-b) signal is one of the
most important pathways for CAF activation as well as tumor
metastasis. VASH2 has been recently reported to be involved
in epithelial–mesenchymal transition and the chemoprevention
ability of cancer cells.(18,45–47) We earlier found that VASH2
might accelerate TGF-b-induced epithelial–mesenchymal tran-
sition and invasiveness of ovarian cancer cells by modulating
TGF-b type I receptor expression, suggesting functional
Fig. 7. Knockdown of VASH2 in gastric cancer
cells suppresses fibroblast activation in vitro. (a)
VASH2 mRNA level in FU97 cells relative to that in
SF-TY cells was determined by real-time RT-PCR
analysis. The VASH2 mRNA expression levels were
normalized to b-actin mRNA level. *P < 0.05 versus
SF-TY cell. (b) VASH2 mRNA level in VASH2
knockdown clones and control mock transfectant
relative to that in parental FU97 cells was
determined by real-time RT-PCR analysis. *P < 0.05
versus parental FU97 cell. (c) Effect of conditioned
media (CM) of gastric cancer cells on fibroblast
migration and proliferation. SF-TY cells were
treated with CM of indicated gastric cancer cells.
Migration and proliferation of SF-TY cells were
analyzed by a modified Boyden chamber assay and
BrdU incorporation assay, respectively. *P < 0.05
versus mock CM. (d) Effect of CM of gastric cancer
cells on ACTA2 mRNA expression in fibroblasts. The
ACTA2 mRNA levels in SF-TY cells treated with CM
of indicated gastric cancer cells for 48 h were
examined by real-time RT-PCR. *P < 0.05 versus
mock CM. All quantitative data show mean  SD.
All experiments were performed at least twice.
Fig. 8. Roles of VASH2 in gastric tumor growth. Schematic illustra-
tion of the roles of VASH2 in gastric tumor growth. VASH2 is pro-
duced from cancer cells and acts on neighboring EC as a
proangiogenic factor in a paracrine manner. In contrast, VASH2 influ-
ences cancer cell proliferation and stromal activation, such as CAF
expansion, by upregulating the expression of EREG, IL-11 and IL-6.
Cancer Sci | December 2017 | vol. 108 | no. 12 | 2349 © 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
on behalf of Japanese Cancer Association.
Original Article
www.wileyonlinelibrary.com/journal/cas Suzuki et al.
links between TGF-b signal and VASH2 action in tumor pro-
gression.(45)
In summary, we propose that VASH2 plays an important
role in tumor progression via stromal activation, such as CAF
expansion, by upregulating the expression of EREG and IL-11,
in addition to its proangiogenic activity (Fig. 8). Further stud-
ies are currently under way to clarify the molecular mechanism
by which VASH2 causes stromal activation. It is also possible
that targeting of VASH2 may be applied as a novel molecu-
lar target therapy for gastric cancers, which is also under
investigation.
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